No Data
Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $69
Stifel analyst Dae Gon Ha maintains $Beam Therapeutics(BEAM.US)$ with a buy rating, and adjusts the target price from $66 to $69.According to TipRanks data, the analyst has a success rate of 46.0%
Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $69
Stifel analyst Benjamin Burnett maintains $Beam Therapeutics(BEAM.US)$ with a buy rating, and adjusts the target price from $103 to $69.According to TipRanks data, the analyst has a success rate of 35
Beam Therapeutics Is Maintained at Buy by Stifel
Express News | Beam Therapeutics Inc : Stifel Raises Target Price to $69 From $66
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
H.C. Wainwright analyst Patrick Trucchio maintains $Beam Therapeutics(BEAM.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 3
No Data
No Data
